Kancera: Progress according to plan - Redeye

Redeye provides a research update following the Q2 2024 report from Kancera. Costs came in slightly below forecasts driven by lower R&D spend. In the operational update released in conjunction with the report, we learnt that the ongoing KANDOVA study might be concucted with fewer patients than initially thought. We maintain our estimates and make minor valuation changes to account for FX fluctuations and the updated cash position.

Länk till analysen i sin helhet: https://www.redeye.se/research/1034247/kancera-progress-according-to-plan?utm_source=finwire&utm_medium=RSS